Omnicell, Inc. (OMCL)
NASDAQ: OMCL · IEX Real-Time Price · USD
30.31
+1.02 (3.48%)
May 3, 2024, 9:40 AM EDT - Market open
Omnicell Revenue
In the year 2023, Omnicell had annual revenue of $1.15B, a decrease of -11.48%. Revenue in the quarter ending December 31, 2023 was $258.85M, a -13.04% decrease year-over-year.
Revenue (ttm)
$1.15B
Revenue Growth
-11.48%
P/S Ratio
1.17
Revenue / Employee
$314,277
Employees
3,650
Market Cap
1.34B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.15B | -148.84M | -11.48% |
Dec 31, 2022 | 1.30B | 163.93M | 14.48% |
Dec 31, 2021 | 1.13B | 239.81M | 26.88% |
Dec 31, 2020 | 892.21M | -4.82M | -0.54% |
Dec 31, 2019 | 897.03M | 109.72M | 13.94% |
Dec 31, 2018 | 787.31M | 74.60M | 10.47% |
Dec 31, 2017 | 712.71M | 16.81M | 2.41% |
Dec 31, 2016 | 695.91M | 211.35M | 43.62% |
Dec 31, 2015 | 484.56M | 43.66M | 9.90% |
Dec 31, 2014 | 440.90M | 60.32M | 15.85% |
Dec 31, 2013 | 380.59M | 66.56M | 21.19% |
Dec 31, 2012 | 314.03M | 68.49M | 27.90% |
Dec 31, 2011 | 245.54M | 23.13M | 10.40% |
Dec 31, 2010 | 222.41M | 8.95M | 4.19% |
Dec 31, 2009 | 213.46M | -38.41M | -15.25% |
Dec 31, 2008 | 251.87M | 38.78M | 18.20% |
Dec 31, 2007 | 213.08M | 58.37M | 37.73% |
Dec 31, 2006 | 154.71M | 33.19M | 27.31% |
Dec 31, 2005 | 121.52M | -2.42M | -1.95% |
Dec 31, 2004 | 123.94M | 21.81M | 21.36% |
Dec 31, 2003 | 102.13M | 14.44M | 16.46% |
Dec 31, 2002 | 87.69M | 789.00K | 0.91% |
Dec 31, 2001 | 86.90M | 19.54M | 29.00% |
Dec 31, 2000 | 67.37M | 12.09M | 21.88% |
Dec 31, 1999 | 55.27M | 7.06M | 14.64% |
Dec 31, 1998 | 48.21M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Brookdale Senior Living | 3.02B |
Agiliti | 1.17B |
Pacira BioSciences | 674.98M |
Ironwood Pharmaceuticals | 442.74M |
Establishment Labs Holdings | 165.15M |
4D Molecular Therapeutics | 20.72M |
Tarsus Pharmaceuticals | 17.45M |
Spyre Therapeutics | 886.00K |
OMCL News
- 1 day ago - Omnicell Announces First Quarter 2024 Results - Business Wire
- 16 days ago - Omnicell Announces XT Amplify - Business Wire
- 24 days ago - Omnicell to Release First Quarter 2024 Financial Results on May 2, 2024 - Business Wire
- 7 weeks ago - Omnicell to Present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum - Business Wire
- 3 months ago - Omnicell Announces Fiscal Year and Fourth Quarter 2023 Results - Business Wire
- 3 months ago - Omnicell to Release Fourth Quarter and Full Year 2023 Financial Results on February 8, 2024 - Business Wire
- 4 months ago - Omnicell Elects Eileen Voynick to Board of Directors - Business Wire
- 5 months ago - Omnicell to Present at the Piper Sandler 35th Annual Healthcare Conference - Business Wire